Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02650375
Other study ID # SIM-128-I-02
Secondary ID
Status Recruiting
Phase Phase 1
First received November 10, 2015
Last updated January 20, 2017
Start date October 2015
Est. completion date February 2018

Study information

Verified date January 2017
Source Jiangsu Simcere Pharmaceutical Co., Ltd.
Contact Shuangling Deng, MS
Phone 86-025-85560000
Email dengshuangling@simcere.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multicenter study designed to assess the safety, tolerability, preliminary efficacy and pharmacokinetics of Metatinib Tromethamine tablet in patients with advanced or metastatic gastric cancer, liver cancer, colorectal cancer,or con squamous NSCLC. Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred. The study will determine whether MET gene mutation, amplification, as well as MET protein overexpression in tumor tissue correlate with treatment efficacy and clinical outcome. The potential PD biomarker for Metatinib will also be explored.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date February 2018
Est. primary completion date October 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients with advanced or metastatic gastric cancer or colorectal cancer who progress after second-line therapy or the above treatment protocol, or patients with advanced or metastatic hepatocellular carcinoma who progress after first-line chemotherapy, interventional therapy or targeted therapy shall be verified by histology or cytology; or patients with advanced or metastatic non-squamous non-small cell lung cancer who cannot be operated or fail to first-line therapy shall be verified by histology or cytology;

- MET gene amplification or protein overexpression(IHC =2+),or exon-14 skipping;

- At least one measurable lesion (RECIST 1.1 );

- At least 4 weeks from the last chemotherapy, radiotherapy or anti-tumor biological products treatment; at least 8 weeks from the last anti-tumor antibody products treatment; at least 6 weeks from the last dose of nitrosourea, mitomycin C or doxorubicin;

- At least 4 weeks from major surgery or trauma, and the wound should fully heal; at least 1 week from minor surgery or trauma (i.e. tissue biopsy or fine needle aspiration);

- Toxicity from previous treatment has to restore to = grade 1, baseline or irreversible (NCI CTC4.0);

- ECOG performance status 0-1;

- Life expectancy =3 months;

- Adequate hematologic function: ANC=1.5×10^9 /L, HB=90g/L(blood transfusion allowed), PLT=100×10^9/L;

- Adequate hepatic function: ALT=3×ULN, AST=3×ULN, TBIL=2×ULN(patients with liver metastases or liver cancer ALT=5×ULN, AST=5×ULN, TBIL=2×ULN), Child-Pugh score=7;

- Adequate renal function: uric acid<500µmol/L, creatinine<1.7mg/dL, proteinuria=2+or=2g/24h , GFR=60 ml/min/1.73m^2;

- PT-INR/APTT=1.5×ULN, Serum sodium, potassium, calcium, magnesium levels =1×ULN(NCI-CTC 4.0);

- Patients signed written informed consent;

- Willingness and capability to comply with protocol requirement and well communicate with investigators.

Exclusion Criteria:

- Severe, uncontrolled medical disorders or active infection, including but not limited to HIV antibody positive, active tuberculosis, HBV DNA copies>10^3/ml;

- Subjects have known or suspected brain metastases;

- Patients must receive other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for palliative local radiation) or traditional Chinese medicine for treatment of cancer during the study;

- Previously received other VEGF/VEGFR small-molecule inhibitors or antibodies therapy, including but not limited to Bevacizumab, Ramucirumab, Aflibercept;

- Previously received other HGF/c-Met small-molecule inhibitors or antibodies therapy, including but not limited to Crizotinib, Cabozantinib, Volitinib, Capmatinib (INC280), BPI-9016M;

- Imaging showed involvement of major blood vessels or nerves by tumor;

- Uncontrolled hypertension (systolic blood pressure>150mmHg and/or diastolic blood pressure>100mmHg after treatment);

- LVEF<50%;

- Apparent heart disease, including congestive heart failure(NYHA III-IV), history of myocardial infarction, or uncontrolled angina within 6 months prior to enrollment;

- Arrhythmias need to be treated, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia or ventricular fibrillation; ECG abnormalities confirmed, including QT interval prolongation (males>450msec, females>470 msec);

- History of hemorrhagic or thrombotic events within 6 months before enrollment, i.e. cerebrovascular accidents(including TIA), pulmonary embolism, spontaneous hemorrhage of tumor;

- Patients need surgery within 28 days, or is expected to require surgery within 28 days after the last dose;

- Uncontrolled cavity effusion, such as large amount of pleural effusion and ascites;

- Gastrointestinal illnesses(i.e., uncontrolled diarrhea or malabsorption) at screening or within 3 months that may affect drug absorption;

- History or suspicious signs of gastrointestinal perforation;

- Concomitant medications that may affect the drug metabolism (i.e. strong CYP3A4 inhibitors or inducer );

- Pregnant or lactating women;

- Subjects of childbearing refused to use medically acceptable methods of contraception until 3 months after the last dose;

- Participate in other clinical trials within 4 weeks prior to enrollment;

- The investigators consider the patients are not suitable for this trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Metatinib Tromethamine
Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.

Locations

Country Name City State
China The First Bethune Hospital of Jilin University Changchun Jilin
China West China Hospital, Sichuan University Chengdu Sichuan
China The First Affiliated Hospital, Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Simcere Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of adverse events until 30 days after the last dose
Secondary Objective response rate every 6 weeks, up to 2 years
Secondary Disease control rate every 6 weeks, up to 2 years
Secondary Progression free survival every 6 weeks, up to 2 years
Secondary Overall survival every 6 weeks, up to 2 years
Secondary Cmax for Metatinib day 1,day 2,day 8,day15,day22
Secondary Cmin for Metatinib day 1,day 2,day 8,day15,day22
Secondary Tmax for Metatinib day 1,day 2,day 8,day15,day22
Secondary AUC for Metatinib day 1,day 2,day 8,day15,day22
Secondary T1/2 for Metatinib day 1,day 2,day 8,day15,day22
Secondary CL for Metatinib day 1,day 2,day 8,day15,day22
See also
  Status Clinical Trial Phase
Recruiting NCT05188209 - A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. Phase 2
Recruiting NCT04492488 - A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer Phase 1/Phase 2
Completed NCT01512745 - Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Phase 3